Appendix Cancer Systemic Chemotherapy
Appendiceal Adenocarcinoma Systemic Chemotherapy
Resources, Referrals, Research and Support
News from ASCO 2012!
Systemic chemotherapy in the setting of unresectable Appendiceal Epithelial Neoplasms (AEN).
Source: J Clin Oncol 30, 2012 (suppl 4; abstr 568)
Author(s): Cathy Eng, Aaron Udell Blackham, Michael J. Overman, Keith F. Fournier, Richard E. Royal, Prianka Gajula, Edward Allen Levine, Robert A. Wolff, Paul F. Mansfield; University of Texas M.D. Anderson Cancer Center, Houston, TX; Wake Forest School of Medicine, Winston-Salem, NC
In brief: AEN is a malignancy including both indolent well-differentiated and highly aggressive signet ring carcinoma. Optimal therapy is believed to be cytoreductive surgery (CRS) followed by heated intraperitoneal chemotherapy (HIPEC).The purpose of this study is to compare SC regimens in treatment-naïve surgically unresectable AEN pts.
Chemotherapy(ies)* for Unresectable Appendix Cancer:659 patients studied btwn 2005 and 2009: 5FU,Folfiri,Folfox
Conclusions: In the treatment of surgically unresectable AEN, combination chemotherapy resulted in improved PFS vs. single agent 5-FU. Quality of life analysis will be reported at a later date. Randomized prospective analysis should be considered.
Systemic Therapy for Advanced Appendix Cancer
Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the National Comprehensive Cancer Network (NCCN) database.
ASCO Abstract No:562
Source:J Clin Oncol 30, 2012 (suppl 4; abstr 562)Author(s): Mohamedtaki Abdulaziz Tejani, Anna ter Veer, Dana Milne, Rebecca Ottsesen, Tanios S. Bekaii-Saab, Al Bowen Benson, Deborah Schrag, Stephen Shibata, John Michael Skibber, Martin R. Weiser, Neal W. Wilkinson, Steven J. Cohen; University of Rochester Medical Center, Rochester, NY; City of Hope, Duarte, CA; Dana-Farber Cancer Institute, Boston, MA; The Ohio State University Medical Center, Columbus, OH; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Fox Chase Cancer Center, Philadelphia, PA
Abstract:
Background: Appendiceal neoplasms are rare and represent 1% of intestinal tumors in the United States. The role and efficacy of modern systemic therapy in advanced appendiceal adenocarcinoma has not been established.
Methods: Patients with recurrent or metastatic appendiceal adenocarcinoma in the NCCN Colorectal Database (2005-2010) were analyzed. Study objectives were to describe and evaluate the efficacy of systemic therapy and investigate relationships with clinicopathologic features. Cox regression analysis was performed to identify predictors of PFS and OS. The hazard ratio and 95% CI from Cox models and median PFS and OS from Kaplan-Meier curves were reported.
Results: Of 177 patients with advanced appendiceal carcinoma, 81 (46%) received systemic therapy for measurable disease and are the focus of this report (patients undergoing IP chemotherapy excluded).
Patient/tumor characteristics: median age 50 (range 20-82), ECOG PS 0/1 (67%/22%), mucinous/non-mucinous (44 %/ 51%), 91% peritoneal and 15% liver metastases. 70% of patients had primary surgical debulking.
Common chemotherapy regimens included FOLFOX with or without bevacizumab (n=30 and n=28), FOLFIRI (n=11), and single-agent fluoropyrimidine (n=7). Among 70 patients with a recorded best response, the response rate (RR) was 46% with 31% stable disease. Median PFS was 1.0 year (95% CI: 0.7-1.9) and OS was 2.1 years (95% CI: 1.7-2.6). Patients with non-mucinous histology, high grade tumors and non-debulking surgery had worse PFS and OS.
Conclusions: Treatment of advanced appendiceal adenocarcinoma at NCCN centers commonly incorporates agents utilized for colorectal cancer. RR, PFS and OS are comparable to those achieved in the treatment of metastatic CRC and support routine use of these regimens in clinical practice. Poor prognostic factors include non-mucinous histology, high grade and not undergoing debulking surgery.
Appendix Cancer Patients Lead Active Lives During Chemo!
Our Pal, Andy, participates in a bike marathon while on chemotherapy!
Connect with other Appendix Cancer systemic chemotherapy patients!
Elaine is on the go!
Elaine enjoys horseback riding in between chemotherapy sessions!
Communicate directly with other Appendix Cancer chemotherapy patients!
Appendix Cancer patients lead active lives during chemotherapy!
Our Pal, Mike, catches "the big one" while on chemotherapy!
Our "Chemo Pals" share helpful tips for living well while on chemo!
Appendix Cancer Chemotherapy Patients Lead Active Lives During Treatment!
Our Pal, Robert, second from right, enjoys a round of golf with his buddies, in between chemotherapy sessions!
Appendix Cancer Patients Celebrate Life!
Robert, front and center, is on chemotherapy this week, but doesn't allow that and his staff to celebrate!
Does Food Interfere with the Effectiveness of Chemotherapy?
Appendix cancer patient, KR, from the USA, will begin systemic chemotherapy treatment, using Folfiri, within a few days. She submitted the following question to the PMP Pals’ Network:
“I read on the internet that some foods may interfere with the effectiveness of chemotherapy. Which foods should I avoid?”
PMP Pals replies:
“We are not aware of any foods that interfere with the effectiveness of chemotherapy.
1. There are a wide variety of chemotherapies. When seeking information, be sure that the information you obtain is specific to the chemotherapy prescribed to you, in this case Folfiri.
2. Always seek advice of this nature from your oncologist and your pharmacist.
3. A helpful source of information, specific to your question is the advice nurse available via the manufacturer/producer of nearly any chemo prescribed for you. The major pharmaceutical companies (e.g. Roche, Teva, etc.) provide telephone advice nurses to answer questions from patients.
The PMP Pals' Network does not endorse the use of online "chat rooms", "message boards", Facebook, etc. for obtaining detailed medical information. Specific medical information should be directed to one's licensed, professional healthcare team.
Taste Disorders Associated with Folfox Folfiri Affect QOL
Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer
Takimoto N, Sugawara S, Iida A, Sakakibara T, Mori K, Sugiura M, Yamamura K, Adachi M.
Source: Dept. of Pharmacy, Kariya Toyota General Hospital. March 2009
Abstract
Taste disorders are frequent occurrences among those patients under the FOLFOX-FOLFIRI regimen for colorectal cancer.
We conducted a study on the development of taste disorders among colorectal cancer patients under this regimen and the effect of such disorders on their QOL. Taste disorders occurred in 58.1%(18/31 cases)of these patients and the disorders affected appetites in 50%(9 cases).
The changes in taste sensations were subtle in most but some described certain tastes as exaggerated. Others reported changes in all taste sensations, including sweet, salty, bitter and sour, as well as deliciousness.
When tested via the QOL Survey Sheet(Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs: QOL-ACD), the QOL was found to have deteriorated significantly in those who stated that taste disorders affected their appetite, in comparison with those who were unaffected. In patients with colorectal cancers and treated with the FOLFOX-FOLFIRI regimen, taste disorders are frequent occurrences.
The poor nutritional state due to a loss of appetite may constitute a factor responsible for a lowering QOL.
PMID: 19295267 [PubMed - indexed for MEDLINE]
How to Prevent Infections for Chemotherapy Patients
Prevent Infections in Cancer Patients
Source: CDC
Prevencion de infecciones en pacientes con cancer
Source: CDC
Appendix Cancer Patient Affected by 5 FU Shortage
Are chemotherapies being hoarded for profit?
This video news report featuring an American appendix cancer patient, is preceeded by a brief advertisement.
Source: CBS News 10.13.11
ASCO Addresses Chemotherapy Shortage
5 Flourourcil (5-FU) Shortage
American Society of Health Systems Pharmacists lists shortages of 5 FU
Source: ASHSP
Additional chemotherapies affected by the shortage:
Capecitabine Tablets (Xeloda)
• Cisplatin Injection
• Doxorubicin Injection
• Irinotecan Injection
• Mitomycin Injection
• Paclitaxel Injection
Source: ASHSP
Additional chemotherapies affected by the shortage:
Capecitabine Tablets (Xeloda)
• Cisplatin Injection
• Doxorubicin Injection
• Irinotecan Injection
• Mitomycin Injection
• Paclitaxel Injection
FDA Lists Drug Shortages
Q&A About Appendix Cancer Chemotherapy
Ken on chemo!
What is appendix cancer chemotherapy?
What type of chemotherapy is prescribed for appendiceal cancer?
Is chemotherapy necessary for the treatment of appendix cancer?
Once thought to be ineffective for the treatment of Appendix Cancer, and Pseudomyxoma Peritonei, systemic chemotherapy treatment has become common during the past decade due to the development of several new colorectal cancer therapies.
Several systemic chemotherapies (many listed below) have become treatment options for Appendix cancer and pseudomyxoma peritonei patients. Systemic chemotherapy targets cancer cells throughout the body and is delivered throughout the bloodstream.
HIPEC, a chemotherapy treatment delivered directly into the peritoneal cavity, is listed on its own link on this website
Systemic chemotherapy targets cancer cells throughout the body and is delivered throughout the bloodstream.
Is systemic chemotherapy an appropriate treatment for appendix cancer?
Participants in "Chemo Pals" are Pseudomyxoma Peritonei and Appendix Cancer patients who exchange information regarding the particular chemotherapy (ies) utilized, including results of their treatment regimens.
Become a "Pal" and begin particpating in our "Chemo Pals Resource & Support Group today!
Here are a variety of informative websites and articles, for your review:
Nutrition Tips for Chemotherapy Patients
Source: Web MD 04.12.11
Definition and Treatments for Neuropathy from Chemotherapy
Source: Sheryl Ness, Mayo Clinic Nurse Educator
MD Anderson Offers Trial Program to Combat Neuropathy
Source: MD Anderson
Questions to Ask Your Oncologist About Chemotherapy
Source: National Institutes of Health
Assay Testing, Cell Based Oncology Assays
Exigon Diagnostics (formerly Oncotech)
Source: Exigon
Avastin (Bevacizumab)
Avastin: Phase III study of Avastin plus chemotherapy in advanced stomach cancer did not meet goals
Source: Roche, Feb 2010
Bevacizumab + Xeliri* an effective alternative to Avastin+5 FU+Leucovorin+Folfiri for metastatic Colorectal Cancer
Source: ESMO-GI, July 2009
Avastin and Xeloda Treatment for Pseudomyxoma Peritonei and Appendix Cancer
Source: Cancer Bio Ther Austria and China, Aug 2009
Catumaxomab (Removab)
Source: NCI
Catumaxomab: Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
Source NIH: January 2009
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Source: NIH 2008
Cetuximab (Erbitux)
Cetuximab (Erbitux) may not improve survival rates for stage III colon cancer cases
Adding Cetuximab to FOLFOX does not improve survival in advanced colon cancers
Source: HemoOnc June 10, 2010
EFGR Study for Colorectal Cancer: Resistance to Cetuximab and Panitumumab
Source: Journal of Clinical Oncology March 2010
Cetuximab for Liver Mets from Colorectal Cancer
Rectal Cancer Response to Cetuximab
(April 2009)
Cetuximab, Defined
Source: National Cancer Institute, 2009
KRAS mutant status helps predict survival for Colorectal Cancer patients treated with Cetuximab, Folifiri, Folfox 6
Source: ESMO GI, June 2009
Erbitux
Erbitux Use for Colon Cancer
Erbitux Q and A
Chemotherapy, General
General Chemotherapy Descriptions
Chemotherapy, General Guide
CenterWatch Clinical Trials Notification Service
Cisplatin
Effects of Cisplatin Exposure
Source: Elsevier 2008
Cisplatin Side Effects
Source: Journal of Clinical Oncology 1986
IP Cisplation Treatment for Peritoneal Carcinomatosis of the Ovaries
Combrestatin
Combrestatin
Clinical Trials
ASCO reviews NEW chemotherapy trials for GI and Colon cancers
Source: ASCO 2009
Doxorubicin
Doxorubicin
Source: Medline
EFGR
EFGR Study for Colorectal Cancer: Resistance to Cetuximab and Panitumumab
Source: Journal of Clinical Oncology March 2010
Biomarkers Predict Outcome of EFGR Targeted Therapy Colorectal Cancers
Source: Journal of the National Cancer Inst, 2009
EFGR definition
Source: NCI
Eloxatin (see also Oxaliplatin)
Eloxatin Approved for Colorectal Cancer
Eloxatin Information Site
Flourouracil
Flourouracil
Folfox and Folfiri
Cetuximab (Erbitux) may not improve survival rates for stage III colon cancer cases
Adding Cetuximab to FOLFOX does not improve survival in advanced colon cancers
Source: HemoOnc June 10, 2010
FolfoxFolfiri
FolfiriFolfiri:metastatic gastric cancer
Source: ASCO 2009
Folfox/Folfiri in lieu of surgery for advanced stage Colorectal Cancer
Source: ASCO 2009
Folfox and Folfiri for metastatic colorectal cancer
Source: Clinical Colorectal Cancer 2005
Folfiri: Systemic Chemotherapy for the Treatment of Pseudomyxoma Peritonei, Mucinous Adenocarcinoma
KRAS mutant status helps predict survival of Colorectal Cancer pts treated w/Cetuximab, Folifiri, Folfox 6
Source: ESMO GI, June 2009
Folfox and Folfiri Phase II Study for Peritoneal Carcinomatosis Professor P Piso, in Regensburg, Germany provides a prospective, multicenter Phase II study evaluating multimodality treatment with pre- and postoperative systemic chemotherapy with FOLFOX/Cetuximab or FOLFIRI/ Cetuximab, complete cytoreductive surgery (CRS), and HIPEC in patients with diagnosed with Peritoneal Carcinomatosis.
For more information, contact:
Prof. Dr. P. Piso
Leitender Oberarzt
Klinik und Poliklinik für Chirurgie
der UniversitätRegensburg
Franz Josef Strauß Allee 11
D-93053 Regensburg
Tel.: 0941-944-6809
Fax: 0941-944-6860
Gastric Cancer
Gastric Cancer Survival Rates increase with Chemotherapy
Source: JAMA, May 2010
Systemic Chemotherapy
Phase II Study Tests Effectiveness of Systemic Chemo for Pseudomyxoma Peritonei
Source: Christies Hospital, Manchester UK, Aug 2008
Pseudomyxoma Peritonei Treatment with Avastin and Xeloda
Source: Cancer Bio Ther (Austria and China) Aug 2009
Pseudomyxoma Peritonei Treatment with Adjuvant Chemotherapy
Source: World Journal of Surgical Oncology 2008
HIPEC
Herception
Herceptin use for Gastric Cancer
Source: ASCO 45th Annual Meeting Report,2009
Iressa
Iressa Clinical Trials
Iressa Studies and Trials
Irinotecan
Irinotecan with 5 FU
KRAS Mutation Testing
Listing of laboratories for KRAS mutation testing
Exigon Diagnostics (formerly Oncotech)
Source: Exigon
Leucovorin
Leucovorin
Mitomycin
Mitomycin
Oxaliplatin
Oxaliplation (see also Eloxatin)
Source: Sanofi Aventis
Oxaliplatin
Sulindac
Sulindac (Clinoril)
Tarceva
Tarceva or Erlotinib
Tacotere
Taxotere (Docetaxel) Use for Stomach Cancer
Xeliri*
Capetcitabine + Irinotecan
Xeloda
Xeloda web site.
Important Info about Xeloda
New Findings About the Effectiveness of Xeloda
Xelox
Xelox (Capecitabine + Oxaliplatin)
Source: Journal of Clinical Oncology, 2004
Isolated Perfusion of Chemotherapy
Regional Chemotherapy via Isolated Perfusion for Cisplatin Resistant Ovarian Cancer
Source: Professor Karl Aigner, Germany 2008
Profile of Prof Karl Aigner
Prof Karl Aigner describes regional perfusion at his clinic in Bavaria via video en espanol
Chemotherapy Resource Section: Articles of General Interest
Is Systemic Chemo the Right Option for Pseudomyxoma Peritonei?
Tips for Keeping Cool this Summer while receiving Chemo
Source: PMP Pals' Network Blog
Is Chemotherapy the Right Choice for You?
Source: PMP Pals' Network Blog
Should US adopt UK's limits on patient chemo costs?
Source: Medline, July 2009
Are all medical treatments worth the high cost?
Source: JNCI, May 2009
Can inhibition of angiogenesis inhibitors result in tumor invasion and metastasis?
Source: Nature Review June 2009
"Chemo Brain": Is it real?
Source: New York Times, Jane Brody, August 2009
Maintenance Chemotherapy
Source: New York Times, July 2009
Suggestions for coping w/"Chemo Brain"
Source: New York Times, Jane E Brody, August 2009
Anti Nausea Medications
Emend (Aprepitant)
Source: Merck
Colorectal Cancer Care
Dr Cathy Eng, Oncologist, MD Anderson, Houston TX
Source: MD Anderson
Coping with Special Needs
Special Needs for Side Effects of Chemotherapy
Coping with Chemo
Additional Chemo Resources
CURE Magazine FREE Online!
Source: CURE Magazine
Click here to subscribe to MedScape for free weekly and daily updates for cancer care!
Health Insurance
Health Insurance Solutions
Poison Control
American Association of Poison Control Centers Toll free number: 1.800.222.1222
FDA
FDA Toll free number: 1.FDA.1088
Refer to the Clinical Trials page for additional information about Chemotherapy options.
Chemotherapies Differ Among Patients
This page is sponsored by Chris and Sherry, USA
Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice.
Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.
Individuals or organizations who plagiarize this copyrighted website will be prosecuted.
The PMP Pals' Network updates our website 364 days per year with a wide variety of new information to keep you informed about maintaining optimal health! Whether you seek information about research studies, health insurance, personal mentoring, diet and exercise, new treatment options, and so much more, the PMP Pals' Network is your "go to" place for information! This page last updated on 02.01.12
